Is Ixekizumab Effective For Genital Psoriasis?

01/23/2018
psoriasis

Ixekizumab significantly improved the appearance of genital psoriasis compared with placebo, according to a recent poster presented at the Winter Clinical Dermatology Conference.

The study included 149 patients with chronic plaque psoriasis and genital psoriasis. For 12 weeks, 75 participants received 80 mg of ixekizumab every 2 weeks and 74 participants received placebo. Using the static Physician’s Global Assessment (sPGA), the researchers measured the severity of genital psoriasis on a 6-point scale, with 0 indicating clear and 5 indicating very severe, at baseline and week 12. The main outcomes included the proportion of patients who achieved sPGA 0 or 1 for genital psoriasis, the proportion of patients who achieved overall sPGA of 0 or 1, the proportion of patients who achieved improvements in genital itch, and the proportion of patients who reported improved sexual activity.

At week 12, 7 out of 10 patients who received ixekizumab achieved clear or almost clear genital skin and overall clear or almost clear skin. Ixekizumab was associated with significantly greater number of participants achieving clear or almost clear genital skin and overall clear or almost clear skin as early as week 1. The response to ixekizumab at week 12 was consistent across all patients, regardless of body surface area involvement at baseline.

In addition, 6 out of 10 patients who received ixekizumab experienced clinically meaningful improvements in genital itch at week 12 and about 8 out of 10 patients reported that their frequency of sexual activity was no longer limited or was rarely limited by genital psoriasis.

“Ixekizumab is an efficacious treatment for moderate to severe genital psoriasis, providing rapid clearance of genital skin,” according to the researchers.

—Melissa Weiss

Reference

Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis. Presented at: The Winter Clinical Dermatology Conference; January 12-17, 2018; Maui, Hawaii.